{ "api_version": "1", "request": { "url": "https://clinicaltrialsfind.com/api/v1/search.json?condition=Gastrooesophageal+Cancer&page=5", "query": { "condition": "Gastrooesophageal Cancer", "page": 5 }, "page_size": 10 }, "pagination": { "page": 5, "page_size": 10, "total_count": 101, "total_pages": 11, "next_page_url": "https://clinicaltrialsfind.com/api/v1/search.json?condition=Gastrooesophageal+Cancer&page=6&page_size=10", "previous_page_url": "https://clinicaltrialsfind.com/api/v1/search.json?condition=Gastrooesophageal+Cancer&page=4&page_size=10" }, "source": "remote", "last_synced_at": "2026-10-11T00:07:25.868Z", "attribution": "Data derived from public ClinicalTrials.gov records. The official record at https://clinicaltrials.gov/ remains the source of truth for current availability, contacts, and full study details.", "notes": [ "This endpoint exposes only public summary fields — no participant contact emails, phone numbers, or scraped investigator contact details.", "For contact information and full protocol detail, follow each trial's `official_url` to the ClinicalTrials.gov record.", "This API is a navigational aid. It does not provide medical advice, eligibility determinations, or compensation guarantees." ], "trials": [ { "nct_id": "NCT01129206", "title": "Pralatrexate and Docetaxel in Treating Patients With Stage IV Esophageal or Gastroesophageal Cancer Who Have Failed Platinum-Based Therapy", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE2" ], "conditions": [ "Adenocarcinoma of the Esophagus", "Adenocarcinomas of the Gastroesophageal Junction", "Recurrent Esophageal Cancer", "Squamous Cell Carcinoma of the Esophagus", "Stage IV Esophageal Cancer" ], "interventions": [ { "name": "pralatrexate", "type": "DRUG" }, { "name": "docetaxel", "type": "DRUG" }, { "name": "fludeoxyglucose F 18", "type": "RADIATION" }, { "name": "positron emission tomography", "type": "PROCEDURE" } ], "intervention_types": [ "DRUG", "RADIATION", "PROCEDURE" ], "sponsor": "Ohio State University Comprehensive Cancer Center", "sponsor_class": "OTHER", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 6, "start_date": "2010-07", "completion_date": null, "has_results": true, "last_update_posted_date": "2016-06-01", "last_synced_at": "2026-10-11T00:07:25.868Z", "location_count": 1, "location_summary": "Columbus, Ohio", "locations": [ { "city": "Columbus", "state": "Ohio" } ], "official_url": "https://clinicaltrials.gov/study/NCT01129206" }, { "nct_id": "NCT03629756", "title": "A Study to Evaluate the Safety and Tolerability of Immunotherapy Combinations in Participants With Advanced Malignancies", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE1" ], "conditions": [ "Non-small Cell Lung Cancer", "Squamous Cell Carcinoma of the Head and Neck", "Breast Cancer", "Colorectal Cancer", "Melanoma", "Bladder Cancer", "Ovarian Cancer", "Endometrial Cancer", "Merkel Cell Carcinoma", "GastroEsophageal Cancer", "Renal Cell Carcinoma", "Castration-resistant Prostate Cancer" ], "interventions": [ { "name": "Etrumadenant", "type": "DRUG" }, { "name": "Zimberelimab", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "Arcus Biosciences, Inc.", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 48, "start_date": "2018-07-24", "completion_date": "2021-09-03", "has_results": false, "last_update_posted_date": "2024-05-24", "last_synced_at": "2026-10-11T00:07:25.868Z", "location_count": 12, "location_summary": "Scottsdale, Arizona • Los Angeles, California • Denver, Colorado + 8 more", "locations": [ { "city": "Scottsdale", "state": "Arizona" }, { "city": "Los Angeles", "state": "California" }, { "city": "Los Angeles", "state": "California" }, { "city": "Denver", "state": "Colorado" }, { "city": "Ann Arbor", "state": "Michigan" } ], "official_url": "https://clinicaltrials.gov/study/NCT03629756" }, { "nct_id": "NCT05717998", "title": "Imaging and Blood-Based Biomarkers for the Evaluation of Early Signs of Myocardial Injury After Thoracic Radiation Therapy", "overall_status": "ACTIVE_NOT_RECRUITING", "study_type": "OBSERVATIONAL", "phases": [], "conditions": [ "Lung Non-Small Cell Carcinoma", "GastroEsophageal Cancer", "Esophagus Cancer" ], "interventions": [ { "name": "Biospecimen Collection", "type": "PROCEDURE" }, { "name": "Computed Tomography", "type": "PROCEDURE" }, { "name": "Magnetic Resonance Imaging of the Heart", "type": "PROCEDURE" }, { "name": "Positron Emission Tomography", "type": "PROCEDURE" } ], "intervention_types": [ "PROCEDURE" ], "sponsor": "Ohio State University Comprehensive Cancer Center", "sponsor_class": "OTHER", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 28, "start_date": "2021-04-02", "completion_date": "2027-04-18", "has_results": false, "last_update_posted_date": "2026-09-24", "last_synced_at": "2026-10-11T00:07:25.868Z", "location_count": 1, "location_summary": "Columbus, Ohio", "locations": [ { "city": "Columbus", "state": "Ohio" } ], "official_url": "https://clinicaltrials.gov/study/NCT05717998" }, { "nct_id": "NCT04522336", "title": "Pembrolizumab and Chemoradiotherapy for the Treatment of Unresectable Gastroesophageal Cancer", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE1" ], "conditions": [ "Clinical Stage III Gastroesophageal Junction Adenocarcinoma AJCC v8", "Clinical Stage IV Gastroesophageal Junction Adenocarcinoma AJCC v8", "Clinical Stage IVA Gastroesophageal Junction Adenocarcinoma AJCC v8", "Clinical Stage IVB Gastroesophageal Junction Adenocarcinoma AJCC v8", "Localized Gastroesophageal Junction Adenocarcinoma", "Locally Advanced Gastroesophageal Junction Adenocarcinoma", "Pathologic Stage III Gastroesophageal Junction Adenocarcinoma AJCC v8", "Pathologic Stage IIIA Gastroesophageal Junction Adenocarcinoma AJCC v8", "Pathologic Stage IIIB Gastroesophageal Junction Adenocarcinoma AJCC v8", "Pathologic Stage IV Gastroesophageal Junction Adenocarcinoma AJCC v8", "Pathologic Stage IVA Gastroesophageal Junction Adenocarcinoma AJCC v8", "Pathologic Stage IVB Gastroesophageal Junction Adenocarcinoma AJCC v8", "Postneoadjuvant Therapy Stage III Gastroesophageal Junction Adenocarcinoma AJCC v8", "Postneoadjuvant Therapy Stage IIIA Gastroesophageal Junction Adenocarcinoma AJCC v8", "Postneoadjuvant Therapy Stage IIIB Gastroesophageal Junction Adenocarcinoma AJCC v8", "Postneoadjuvant Therapy Stage IV Gastroesophageal Junction Adenocarcinoma AJCC v8", "Postneoadjuvant Therapy Stage IVA Gastroesophageal Junction Adenocarcinoma AJCC v8", "Postneoadjuvant Therapy Stage IVB Gastroesophageal Junction Adenocarcinoma AJCC v8", "Unresectable Gastroesophageal Junction Adenocarcinoma" ], "interventions": [ { "name": "Docetaxel", "type": "DRUG" }, { "name": "Fluorouracil", "type": "DRUG" }, { "name": "Oxaliplatin", "type": "DRUG" }, { "name": "Pembrolizumab", "type": "BIOLOGICAL" }, { "name": "Radiation Therapy", "type": "RADIATION" } ], "intervention_types": [ "DRUG", "BIOLOGICAL", "RADIATION" ], "sponsor": "M.D. Anderson Cancer Center", "sponsor_class": "OTHER", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 16, "start_date": "2020-09-16", "completion_date": "2026-08-07", "has_results": false, "last_update_posted_date": "2026-08-13", "last_synced_at": "2026-10-11T00:07:25.868Z", "location_count": 1, "location_summary": "Houston, Texas", "locations": [ { "city": "Houston", "state": "Texas" } ], "official_url": "https://clinicaltrials.gov/study/NCT04522336" }, { "nct_id": "NCT03165994", "title": "APX005M With Concurrent Chemoradiation for Resectable Esophageal and Gastroesophageal Junction Cancers", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE2" ], "conditions": [ "Esophageal Cancer", "GastroEsophageal Cancer" ], "interventions": [ { "name": "APX005M", "type": "DRUG" }, { "name": "Radiation Therapy", "type": "RADIATION" }, { "name": "Paclitaxel", "type": "DRUG" }, { "name": "Carboplatin", "type": "DRUG" }, { "name": "Surgical resection of tumor", "type": "PROCEDURE" } ], "intervention_types": [ "DRUG", "RADIATION", "PROCEDURE" ], "sponsor": "Apexigen America, Inc.", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 34, "start_date": "2017-10-06", "completion_date": "2023-02-21", "has_results": true, "last_update_posted_date": "2024-05-02", "last_synced_at": "2026-10-11T00:07:25.868Z", "location_count": 10, "location_summary": "Tucson, Arizona • Duarte, California • San Francisco, California + 7 more", "locations": [ { "city": "Tucson", "state": "Arizona" }, { "city": "Duarte", "state": "California" }, { "city": "San Francisco", "state": "California" }, { "city": "Washington D.C.", "state": "District of Columbia" }, { "city": "New York", "state": "New York" } ], "official_url": "https://clinicaltrials.gov/study/NCT03165994" }, { "nct_id": "NCT05205343", "title": "Trans-Pacific Multicenter Collaborative Study of Minimally Invasive Proximal Versus Total Gastrectomy for Proximal Gastric and Gastroesophageal Junction Cancers", "overall_status": "RECRUITING", "study_type": "OBSERVATIONAL", "phases": [], "conditions": [ "Gastrostomy", "Gastric", "GastroEsophageal Cancer" ], "interventions": [ { "name": "Standard of Care", "type": "OTHER" }, { "name": "Control Group", "type": "OTHER" } ], "intervention_types": [ "OTHER" ], "sponsor": "M.D. Anderson Cancer Center", "sponsor_class": "OTHER", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 20, "start_date": "2022-05-11", "completion_date": "2028-05-31", "has_results": false, "last_update_posted_date": "2026-08-21", "last_synced_at": "2026-10-11T00:07:25.868Z", "location_count": 2, "location_summary": "Rochester, Minnesota • Houston, Texas", "locations": [ { "city": "Rochester", "state": "Minnesota" }, { "city": "Houston", "state": "Texas" } ], "official_url": "https://clinicaltrials.gov/study/NCT05205343" }, { "nct_id": "NCT00539617", "title": "Chemotherapy & Erlotinib in Treating Patients w/ Esophageal or Gastroesophageal Cancer That Cannot Be Removed by Surgery", "overall_status": "TERMINATED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE2" ], "conditions": [ "Esophageal Cancer" ], "interventions": [ { "name": "Erlotinib", "type": "DRUG" }, { "name": "5-fluorouracil", "type": "DRUG" }, { "name": "Leucovorin", "type": "DRUG" }, { "name": "Oxaliplatin", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "University of California, San Francisco", "sponsor_class": "OTHER", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 7, "start_date": "2007-10-05", "completion_date": "2011-05-12", "has_results": true, "last_update_posted_date": "2020-03-23", "last_synced_at": "2026-10-11T00:07:25.868Z", "location_count": 1, "location_summary": "San Francisco, California", "locations": [ { "city": "San Francisco", "state": "California" } ], "official_url": "https://clinicaltrials.gov/study/NCT00539617" }, { "nct_id": "NCT01365130", "title": "Chemotherapy for Patients With Gastroesophageal Cancers Who Have Progressed After One Prior Chemo Regimen", "overall_status": "TERMINATED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE2" ], "conditions": [ "Esophageal", "Gastrooesophageal Cancer", "Gastric Cancer" ], "interventions": [ { "name": "jevtana", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "howard safran", "sponsor_class": "OTHER", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 15, "start_date": "2011-06", "completion_date": "2013-08", "has_results": true, "last_update_posted_date": "2019-04-12", "last_synced_at": "2026-10-11T00:07:25.868Z", "location_count": 3, "location_summary": "Pawtucket, Rhode Island • Providence, Rhode Island", "locations": [ { "city": "Pawtucket", "state": "Rhode Island" }, { "city": "Providence", "state": "Rhode Island" }, { "city": "Providence", "state": "Rhode Island" } ], "official_url": "https://clinicaltrials.gov/study/NCT01365130" }, { "nct_id": "NCT04499924", "title": "Tucatinib, Trastuzumab, Ramucirumab, and Paclitaxel Versus Paclitaxel and Ramucirumab in Previously Treated HER2+ Gastroesophageal Cancer", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE2", "PHASE3" ], "conditions": [ "Gastric Adenocarcinoma", "Gastroesophageal Junction Adenocarcinoma", "Esophageal Adenocarcinoma" ], "interventions": [ { "name": "tucatinib", "type": "DRUG" }, { "name": "trastuzumab", "type": "DRUG" }, { "name": "ramucirumab", "type": "DRUG" }, { "name": "paclitaxel", "type": "DRUG" }, { "name": "tucatinib placebo", "type": "OTHER" }, { "name": "trastuzumab placebo", "type": "OTHER" } ], "intervention_types": [ "DRUG", "OTHER" ], "sponsor": "Seagen Inc.", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 17, "start_date": "2021-03-22", "completion_date": "2024-04-17", "has_results": true, "last_update_posted_date": "2025-01-22", "last_synced_at": "2026-10-11T00:07:25.868Z", "location_count": 30, "location_summary": "Birmingham, Alabama • Phoenix, Arizona • Tucson, Arizona + 27 more", "locations": [ { "city": "Birmingham", "state": "Alabama" }, { "city": "Phoenix", "state": "Arizona" }, { "city": "Tucson", "state": "Arizona" }, { "city": "Duarte", "state": "California" }, { "city": "Santa Monica", "state": "California" } ], "official_url": "https://clinicaltrials.gov/study/NCT04499924" }, { "nct_id": "NCT03125200", "title": "Study of ADCT-502 in Patients With Advanced Solid Tumors Withhuman Epidermal Growth Factor Receptor-2 (HER2) Expression", "overall_status": "TERMINATED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE1" ], "conditions": [ "Breast Cancer", "Non Small Cell Lung Cancer", "GastroEsophageal Cancer", "Bladder Cancer" ], "interventions": [ { "name": "ADCT-502", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "ADC Therapeutics S.A.", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 21, "start_date": "2017-05-18", "completion_date": "2018-04-05", "has_results": true, "last_update_posted_date": "2021-02-01", "last_synced_at": "2026-10-11T00:07:25.868Z", "location_count": 4, "location_summary": "Palo Alto, California • Buffalo, New York • New York, New York + 1 more", "locations": [ { "city": "Palo Alto", "state": "California" }, { "city": "Buffalo", "state": "New York" }, { "city": "New York", "state": "New York" }, { "city": "San Antonio", "state": "Texas" } ], "official_url": "https://clinicaltrials.gov/study/NCT03125200" } ] }